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Nucleophosmin-anaplastic lymphoma kinase–expressing (NPM-ALK+) T-cell lymphoma is an aggressive form of
cancer that commonly affects children and adolescents. The expression of NPM-ALK chimeric oncogene results
from the chromosomal translocation t(2;5)(p23;q35) that causes the fusion of the ALK and NPM genes. This
translocation generates the NPM-ALK protein tyrosine kinase that forms the constitutively activated NPM-ALK/NPM-
ALK homodimers. In addition, NPM-ALK is structurally associated with wild-type NPM to form NPM/NPM-ALK
heterodimers, which can translocate to the nucleus. The mechanisms that sustain the stability of NPM-ALK are not
fully understood. SUMOylation is a posttranslational modification that is characterized by the reversible conjugation
of small ubiquitin-like modifiers (SUMOs) with target proteins. SUMO competes with ubiquitin for substrate binding
and therefore, SUMOylation is believed to protect target proteins from proteasomal degradation. Moreover,
SUMOylation contributes to the subcellular distribution of target proteins. Herein, we found that the SUMOylation
pathway is deregulated in NPM-ALK+ T-cell lymphoma cell lines and primary lymphoma tumors from patients. We
also identified Lys24 and Lys32 within the NPM domain as the sites where NPM-ALK conjugates with SUMO-1 and
SUMO-3. Importantly, antagonizing SUMOylation by the SENP1 protease decreased the accumulation of NPM-ALK
and suppressed lymphoma cell viability, proliferation, and anchorage-independent colony formation. One possible
mechanism for the SENP1-mediated decrease in NPM-ALK levels was the increase in NPM-ALK association with
ubiquitin, which facilitates its degradation. Our findings propose a model in which aberrancies in SUMOylation
contribute to the pathogenesis of NPM-ALK+ T-cell lymphoma. Unraveling such pathogenic mechanisms may lead
to devising novel strategies to eliminate this aggressive neoplasm.
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Nucleophosmin-anaplastic lymphoma kinase–expressing (NPM-ALK+)
T-cell lymphoma is an aggressive non-Hodgkin’s lymphoma that is
frequently encountered in children and young adults [1]. The expression
of NPM-ALK oncogene results from a chromosomal translocation that
leads to the fusion of theALK gene on 2p23 and theNPM gene on 5q35
[2]. The NPM-ALK oncogene encodes the expression of NPM-ALK
chimeric tyrosine kinase. NPM-ALK induces lymphomagenic effects
through the formation of the constitutively activated NPM-ALK/
NPM-ALK homodimers, which reside in the cytoplasm and possess
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proteins including JAK/STAT, PI3K/AKT, MAP kinases, and IGF-IR
[3–11]. NPM-ALK is also capable of forming heterodimers that are
composed of wild-type NPM and NPM-ALK. Because wild-type NPM
contains a nuclear localization signaling domain, the NPM/NPM-ALK
heterodimers have ability to translocate to the nucleus [12]. The
biological impact of the translocation of NPM-ALK to the nucleus is not
completely understood. At least one study suggested that proteins with
antiapoptotic potential translocate to the nucleus and interact with
NPM-ALK [13]. Notably, the mechanisms that promote the stability
and accumulation of NPM-ALK in the lymphoma cells are not
completely understood.
SUMOylation is a posttranslational modification that is charac-
terized by the reversible conjugation of small ubiquitin-like modifiers
(SUMOs)—SUMO-1, SUMO-2, and SUMO-3—with their target
proteins [14–17]. Whereas SUMO-2 and SUMO-3 are 97%
identical, they demonstrate only 50% sequence resemblance with
SUMO-1. It is unclear whether SUMO-4, another member of the
SUMO proteins, is conjugated to target proteins in vivo[18,19].
SUMO-4 is also unique in that its expression is mainly detected in the
kidneys, spleen, and lymph nodes, unlike SUMO-1 and SUMO-2/3
that are ubiquitously expressed [18]. The regulation of SUMOylation
is ensued via a cascade of SUMO-specific ligases E1, E2, and E3,
which warrants that appropriate targets are modified by SUMO
[20–24]. SUMOylation is also regulated by the sentrin-specific family
of proteases (SENPs) including SENP1-3 and SENP5-7 [25–27].
The role of SENPs encompasses removal of SUMO from target
proteins, thus reversing the effects induced by SUMOylation.
Although SUMOylation shares similarities with ubiquitination, it
has been shown that SUMO proteins compete with ubiquitin for
substrate binding; thus, SUMOylation appears to protect target
proteins from proteasomal degradation [28–30]. In addition to
enhancing protein stability, SUMO proteins are involved in
subcellular localization and distribution of modified proteins as well
as inter- and intramolecular interactions of target substrates, which
affect processes essential for normal and abnormal cellular
homeostasis [31–34].
It has been demonstrated that SUMOylation plays a key role in
cancer pathogenesis. For instance, SUMOylation inhibits cancer
establishment through stabilization of tumor suppressor genes or
promotes cancer development through stabilization of oncogenes
[15,35–43]. Because it is also involved in cellular processes that
preserve genomic integrity, such as DNA damage repair, it is thought
that aberrancies in SUMOylation possess the ability to promote
progression and dissemination, and to initiate therapeutic resistance
in cancer cells [44–49].
In this study, we hypothesized that SUMOylation aberrancies exist
in and contribute to the pathogenesis of NPM-ALK+ T-cell
lymphoma. In support of this idea, we found that the SUMOylation
pathway is abnormally upregulated in NPM-ALK+ T-cell lymphoma
cell lines and ALK+ primary lymphoma tumors from patients.
Moreover, we found that SUMO-1 and SUMO-3 are conjugated to
two specific lysine residues, namely, Lys24 and Lys32, located in the
NPM domain of NPM-ALK. Importantly, antagonism of SUMOy-
lation by the SENP1 protease decreased nuclear and cytoplasmic
expression of the NPM-ALK protein. The negative regulatory effects
of de-SUMOylation by SENP1 on NPM-ALK led to suppression of
lymphoma cell viability, proliferation, and anchorage-independent
colony formation.Materials and Methods
Identifying Potential SUMO Consensus Motifs in NPM-ALK
To identify potential SUMO consensus motifs in NPM-ALK
protein, the web-based algorithm SUMOplot (http://www.abgen-
t.com/sumoplot) was used. After entering the amino acid sequence of
NPM-ALK (GenBank ID: AAA58698.1) into SUMOplot, potential
consensus motifs were identified showing different degrees of
probability of conjugation with SUMO. Although the web-based
algorithm selects ≥0.65 as a high-probability cutoff, we opted for a
more stringent probability cut off of ≥0.85 to avoid the possibility of
false-positive results.
Cell Lines
Five previously characterized NPM-ALK+ T-cell lymphoma cell
lines were used in this study including Karpas 299, DEL, SUP-M2,
SR-786, and SU-DHL-1 (DSMZ, Germany). The T lymphoblastic
leukemia/lymphoma cell line Jurkat (ATCC, Manassas, VA) was used
as a positive control (http://www.cellsignal.com/products/pri-
mary-antibodies/sumo-1-c9h1-rabbit-mab/4940?hit=produc-
tId&ntt=4940), and the renal cell carcinoma cell line 786-O (ATCC)
was used as a negative control (unpublished data from our lab) for
SUMO protein expression. Jurkat cells were also used as the host cells
in the protein degradation experiments. The normal human
peripheral blood pan-T lymphocytes were purchased from StemCell
Technologies (Vancouver, British Columbia, Canada). Cells were
maintained in RPMI 1640 medium (HyClone, South Logan, UT)
supplemented with 10% FBS (Sigma, St. Louis, MO), glutamine
(2 mM), penicillin (100 U/ml), and streptomycin (100 μg/ml) at
37°C in humidified air enriched with 5% CO2.
Antibodies
Antibodies used included SUMO-1 (catalogue number: 4940),
SUMO-2/3 (4971), SENP1 (11929), ubiquitin (3933), Myc-tag
(2276), and lamin A/C (3032) (Cell Signaling Technology, Danvers,
MA); ALK (M7195; DAKO, Carpenteria, CA); Alexafluor 647
anti-mouse secondary antibody (ab150115; Abcam, Cambridge,
MA); and β-actin (a5316; Sigma).
Primary Lymphoma Tumors from Patients
Approval of the Institutional Review Board was granted before
performing experiments in human tissues. Proteins were extracted
from formalin-fixed and paraffin-embedded (FFPE) tissue sections
from primary ALK+ T-cell lymphoma tumors by using the
Qproteome FFPE Tissue Kit (Qiagen, Germantown, MD). Briefly,
2.0-μm sections were subjected to a sequence of deparaffinization in
xylene and concentration gradients of ethanol. Areas of interest,
which were previously identified by using hematoxylin and eosin–
stained sections and light microscopy, were excised from the slides
and transferred to collection tubes. For each extraction procedure,
6.0 μl of β-mercaptoethanol was added to 94 μl of Extraction Buffer
EXB Plus to obtain a working solution (final volume: 100 μl). The
working solution was added to the tube containing the excised tissue
and admixed using vortexing. Tubes were then sealed and incubated
on ice for 5 minutes, and then mixed again by vortexing. The samples
were incubated on a heating block at 100°C for 20 minutes.
Thereafter, samples were incubated in an oven with rotators at 80°C
for 2 hours. After incubation, the tubes were held at 4°C for 1 minute
and then unsealed. The samples were subjected to centrifugation for
15 minutes at 14,000× g at 4°C. The supernatant containing the
Table 1. Primers Used to Generate NPM-ALKK24R andNPM-ALKK32RConstructs by Site-Directed
Mutagenesis (F: Forward; R: Reverse).
NPM-ALKK24R (F): 5’-TTTTCGGTTGTGAACTACGGGCCGACAAAGATTATC-3’
NPM-ALKK24R (R): 5’-GATAATCTTTGTCGGCCCGTAGTTCACAACCGAAAAG-3’
NPM-ALKK32R (F): 5’-GCCGACAAAGATTATCACTITCGCGTGGATAATGATGAAAATGAG-3’
NPM-ALKK32R (R): 5’-CTCATTTTCATCATTATCCACGCGAAAGTGATAATCTTTG
TCGGC-3’
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Extracted proteins were used in Western blotting (WB) assays as
described below.
Immunoprecipitation and WB
Cells were lysed using lysis buffer containing 25 mM HEPES
(pH 7.7), 400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.5%
Triton X-100, 0.1 mM phenylmethylsulfonyl fluoride, 2 mM
dithiothreitol, and 100× protease and phosphatase inhibitor cocktails
(Thermo Scientific). In addition, N-ethylmaleimide (10 mM)
(Thermo Scientific) was used to inhibit de-SUMOylation in the
immunoprecipitation experiments [50]. For immunoprecipitation,
protein A/G agarose beads (Millipore, Billerca, MA) were blocked
with 5% bovine serum albumin overnight to reduce nonspecific
binding. Lysates were precleared using 2.5 μg normal IgG with
rocking for 1 hour at 4°C, followed by centrifugation for 1 minute at
13,000× g and removal of supernatant. Thereafter, 800 μg of lysate
was incubated with 2.5 μg of primary antibody or mouse IgG control
antibody along with the blocked protein A/G agarose beads overnight
at 4°C. Next day, immunocomplexes were spun and supernatant was
removed. The beads were washed three times with cold phosphate-
buffered saline solution for 15 minutes each at 13,000× g and once
with lysis buffer, and then resuspended with 2× sample buffer
(Bio-Rad, Hercules, CA). Then, samples were subjected to WB.
For WB, cells were subjected to lysis as described above. Total
protein concentrations were measured using the Bio-Rad protein
assay. The OD values were obtained using an ELISA plate reader
(Bio-Tek Instruments, Winooski, VT). Proteins (50 μg) were
subjected to electrophoresis with sodium dodecyl sulfate on 8%
polyacrylamide gels (SDS-PAGE). Proteins were transferred to
polyvinylidene fluoride membranes and probed with primary
antibodies and with horseradish peroxidase–conjugated secondary
antibodies (GE Healthcare, Cardiff, UK), and then detected using a
chemiluminescence-based kit (Amersham Life Sciences, Arlington
Heights, IL).
Recombinant Proteins
The NPM-ALK recombinant protein was generated using the
TnT T7/SP6 Coupled Rabbit Reticulocyte Lysate System
(Promega, Fitchburg, WI). The template for the TnT reaction
was a previously described and repeatedly used plasmid [9,10].
The following reaction components were assembled in a micro-
centrifuge tube: TnT Rabbit Reticulocyte Lysate, TnT Reaction
Buffer, TnT T7 RNA Polymerase, Amino Acid Mixture Minus
Leucine (1.0 mM), Amino Acid Mixture Minus Methionine
(1.0 mM), RNasin Ribonuclease Inhibitor (40 U/μl), NPM-ALK
plasmid template, Transcend Biotin-Lysyl-tRNA, and nuclease-
free H2O. The mixture was incubated at 30°C for 90 minutes. An
aliquot of this mixture was analyzed by WB to confirm the correct
translation of NPM-ALK.SUMOylation Assay
In vitro SUMOylation assay was performed using the SUMOlink
SUMO-1 and SUMO-2/3 Kits (Active Motif, Carlsbad, CA). Briefly,
the following components were assembled in a microcentrifuge tube:
protein buffer; SUMOylation buffer (5×); NPM-ALK recombinant
protein; E1 activating enzyme; E2 conjugating enzyme; SUMO-1,
SUMO-2, or SUMO-3 protein; and nuclease-free H2O. In a separate
assay, SUMO proteins were substituted with their corresponding
forms mutated at a single amino acid (point mutation), which were
provided in the kit as controls. The mixtures were incubated at 30°C
for 3 hours. The reactions were stopped by adding equal volumes of
2× SDS-PAGE loading buffer, and proteins were detected by WB.
Site-Directed Mutagenesis and PCR
NPM-ALKK24R, NPM-ALKK32R, and NPM-ALKK24,32R con-
structs, where lysine was replaced by arginine, were generated by
using the QuickChange II XL Site-Directed Mutagenesis kit (Agilent
Technologies, Santa Clara, CA). Primer sequences are shown in
Table 1.
The PCR products were transformed using MaxEfficiency DH5α
competent cells (Invitrogen, Carlsbad, CA), and the transformation
products were plated on ampicillin-resistant plates. Colonies
containing the correct insert were confirmed by direct sequencing
and amplified in ampicillin-containing Luria Bertani Broth (LB)
overnight at 37°C with shaking. Next day, colonies were processed
with the QiaPrep Spin Miniprep Kit (Qiagen) to isolate plasmids. For
in vitro SUMOylation assays, mutated plasmids were used as
templates for the TnT reactions to create mutated recombinant
proteins.
Transfection
Transfection of Jurkat cells using the wild-type NPM-ALK,
NPM-ALKK24R, NPM-ALKK32R, or NPM-ALKK24,32R plasmid was
performed using electroporation and theNucleofector System (Solution
V, Program X-001; Lonza). Thereafter, cells were incubated for
48 hours. TheNPM-ALK+ T-cell lymphoma cell lines were transfected
with the SENP1 expression plasmid (Origene, Rockville, MD) using
electroporation and the Amaxa 4D nucleofection system (Solution SF,
Program CA-150; Lonza, Houston, TX). In some experiments, after
transfection of SENP1, cells were treated with MG132 (Sigma) for
24 hours to examine the effects of proteasome inhibition.
Protein Degradation Assay
Cells were transfected, as described above, with wild-type or mutated
NPM-ALK plasmids for 48 hours and treated with 100 μg/ml
cycloheximide (CHX, Sigma) for 24 and 48 hours. Then, cells were
harvested and subjected to lysis and WB.
Subcellular Fractionation
The Nuclear/Cytosol Fractionation kit (BioVision, Milipitas, CA)
was used according to the manufacturer’s instructions. Briefly, cells
were collected by centrifugation at 600× g for 5 minutes at 4°C. The
CEB-A buffer, containing DTT and protease inhibitors, was added,
and samples were spun at 500× g for 3 minutes at 4°C. The
supernatant was removed, and the pellet was resuspended in the
CEB-A mix and subjected to vigorous vortexing for 15 seconds to
fully resuspend the pellet. Thereafter, samples were incubated on ice
for 10 minutes. Ice-cold CEB-B buffer was added to the tube, which
was subjected to vortexing and placed on ice for 1 minute, and then
spun at maximum speed for 5 minutes. Immediately, the supernatant
Figure 1. SUMO proteins are upregulated and SENP1 protease is downregulated in NPM-ALK+ T-cell lymphoma. (A) WB studies show
very low levels of expression of SUMO-1 and SUMO-2/3 proteins in normal human T lymphocytes. In contrast, overexpression of
SUMO-2/3 protein is present in the five NPM-ALK+ T-cell lymphoma cell lines Karpas 299, SR-786, DEL, SUP-M2, and SU-DHL-1. In
addition, increased expression of SUMO-1 protein is seen in majority of the lymphoma cell lines including Karpas 299, SR-786, and
SU-DHL-1. Moreover, high levels of expression of the SENP1 protease are detected in the normal human T lymphocytes compared with
much lower levels in the five lymphoma cell lines. The Jurkat and 786-O cells were used as positive and negative controls, respectively, for
the expression of the SUMO proteins. Notably, Jurkat cells that express high levels of the SUMO proteins demonstrate much lower levels
of SENP1 than the 786-O cells that lack the expression of SUMO proteins. β-Actin was used as a loading control. (B) Densitometry studies
of SUMO and SENP1 proteins relative to β-actin support the findings of the WB. (C) WB performed on protein extracted from FFPE tissue
sections collected from 15 patients’ lymphoma tumors. The patient samples were divided into two groups—1 to 7 (left panel) and 8 to 15
(right panel)—and lysates from normal human T lymphocytes (TL) were analyzed. It is important to notice that the quality of the FFPE
tissue sections varied significantly, and therefore, β-actin showed unequal protein levels among these samples. Nonetheless, WB
revealed a pattern of expression similar to the cell lines in which SUMO-2/3 was overexpressed in all patients, and SUMO-1 was
upregulated in 9 of the 15 patients. In clear contrast, SENP1 was decreased in 13 of the 15 patients. β-Actin was used as a loading control.
(D) Densitometry studies of the WB bands of SUMO-1, SUMO-2/3, and SENP1 proteins relative to β-actin bands are shown. Despite the
variable levels of β-actin in the lysates from patients’ FFPE tumors, densitometry supported the general increase in SUMO proteins and
decrease in SENP1 protease in these samples.
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tube. The residual pellet was washed five times in ice-cold PBS by
centrifugation at maximum speed for 1 minute to prevent cytoplas-
mic extraction contamination. Then, the pellet was resuspended in
ice-cold Nuclear Extraction buffer (NEB), subjected to vortexing for
15 seconds, and then returned to ice for 10 minutes. This step was
repeated four times. Finally, samples were subjected to centrifugation
at maximum speed for 15 minutes, and the supernatant (containing
nuclear extract) was transferred into a prechilled tube.
Immunofluorescence Staining
Cells were first transfected with empty vector (EV) or Myc-tagged
SENP1 for 24 hours. Thereafter, cytospins were prepared followed by
fixation with 4% paraformaldehyde at the following time points:
0 minute, 15 minutes, 30 minutes, 1 hour, 3 hours, 6 hours,
12 hours, 24 hours, and 48 hours. After fixation, cells were subjected to
permeabilization with 0.2% Triton-X in PBS for 30 minutes at room
temperature. Subsequently, cells were blocked with 0.3% Triton-X/2%
BSA in PBS solution for 1 hour at room temperature. Thereafter,Myc-tag
primary antibody was added at 1:2000 dilution to detect exogenous
SENP1, and slides were incubated at 4°C overnight. The following day,
slides were washed three times in PBS, and Alexafluor 647 fluorochro-
me-conjugated secondary antibody was added at 1:200 dilution for
1.5 hours at room temperature. Thereafter, slides were washed three times
in PBS and counterstained with 4’,6-diamidino-2-phenylindole (DAPI).
Prolong Gold Antifade Mountant (Invitrogen) was added; slides were
coverslipped and sealed with nail polish to prevent dehydration. Images
were captured usingDeltavision Image Restorationmicroscope (Olympus
IX71; GE Healthcare; total magnification is ×400).
Cell Viability Assay
The CellTiter 96 AQueous One Solution Cell Proliferation Assay
(MTS) kit (Promega) was used. Cells were seeded in 96-well plates at a
concentration of 1.0 × 104 cells/well in 100 μl of RPMI supplemented
with 10% FBS. TheMTS reagent was then added and incubated at 37°C
in a humidified chamber containing 5% CO2 in air for approximately
4 hours.ODmeasurementswere obtained by using anELISAplate reader.
Cell Proliferation Assay
The 5-bromo-2’-deoxyuridine (BrdU) assay kit (ExAlpha, Shirley, MA)
was used. Briefly, 2.0 × 105 cells/ml were plated into a 96-well plate. The
BrdU labelwas added at a dilution of 1:500, and the platewas incubated for
24 hours at 37°C. Cells were fixed for 30 minutes at room temperature.
The anti-BrdU antibody was added for 1 hour after washing, followed by
peroxidase goat anti-mouse IgG conjugate (1:2000 dilution) for
30 minutes. Thereafter, the 3,3’,5,5’-tetramethylbenzidine peroxidase
substrate was added, and the plate was incubated for 30 minutes at
room temperature in the dark. Finally, the acid Stop Solution was added,
and the plate was read at 450 nm by using an ELISA plate reader.
Anchorage-Independent Colony Formation Assay
Transfected cells were resuspended to eliminate clumping and then
added in 1:10 (v/v) ratio to 3 ml of methylcellulose (Methocult
H4230, StemCell Technologies). Tubes were gently inverted several
times. Then, 1.0 ml of the mix was divided into 24-well plates in
triplicate. Plates were placed in a humidified incubator at 37°C in 5%
CO2 for 7 days, and p-iodonitrotetrazolium violet was added for
24 hours for staining. Colonies were visualized using the AlphaIma-
ger system (Alpha Innotech, San Leonardo, CA).Results
Potential SUMO Consensus Motifs in NPM-ALK Proteins
To determine whether SUMO consensus motifs exist within the
NPM-ALK amino acid sequences, we used the web-based algorithm
SUMOplot, which identified several lysine residues that could
represent potential conjugation between SUMO and NPM-ALK
(Supplementary Figure 1). The two sites with the highest probability
to conjugate with SUMO proteins were Lys24 (probability = .91)
and Lys32 (probability = .85).
Expression of SUMO Proteins and SENP1 Protease in
NPM-ALK+ T-Cell Lymphoma
Thereafter, we performed screening WB analysis that showed
SUMO-2/3 protein to be universally overexpressed in the NPM-ALK+
T-cell lymphoma cell lines Karpas 299, SR-786, DEL, SUP-M2, and
SU-DHL-1 compared with its lower levels in normal human T
lymphocytes (Figure 1A). In addition, SUMO-1 is overexpressed in
Karpas 299, SR-786, and SU-DHL-1 cells. In contrast, SENP1 protein,
the major suppressor of SUMO conjugation, was substantially decreased
in all of the lymphoma cell lines (Figure 1A). The Jurkat and 786-O cells
were used as positive and negative controls, respectively, for SUMO
expression. Densitometry analysis of the expression of each protein
normalized to β-actin is also shown (Figure 1B). Similar patterns of
expression of SUMO-1, SUMO-2/3, and SENP1 were found in the
lymphoma primary tumors from patients when compared with normal
humanT lymphocytes (Figure 1C). Because the quality of the FFPE tissue
sections varied significantly, β-actin showed unequal protein levels.
Nevertheless, densitometry analysis of the WB bands for each protein
normalized to β-actin supported that SUMO-2/3 is upregulated in all of
the patients and SUMO-1 is upregulated in 9 of 15 patients included in
our study (Figure 1D). In addition, densitometry showed that SENP1
levels are decreased in the 13 of the 15 patient samples compared with T
lymphocytes (Figure 1D). Collectively, these results support that the
SUMOylation proteins are deregulated inNPM-ALK+ T-cell lymphoma.
Physical Association and Interaction between SUMO Proteins
and NPM-ALK
To test whether SUMO proteins are physically associated with
NPM-ALK, immunoprecipitation of endogenous NPM-ALK protein was
performed inKarpas 299 and SR-786 cells using an anti-ALK antibody, and
WB was then used using an anti–SUMO-1 or SUMO-2/3 antibody. The
SUMO proteins were physically associated with NPM-ALK (Figure 2A).
Furthermore, an in vitro SUMOylation assay showed that all SUMO
modifiers are capable of SUMOylating NPM-ALK, as indicated by the
presence of the higher–molecular weight bands above the baseline
NPM-ALK protein bands (Figure 2B). In contrast, SUMO-1 and
SUMO-2 mutated at a single amino acid (point mutation) induced
much less pronounced SUMOylation of NPM-ALK. In addition,
mutated SUMO-3 failed to SUMOylate NPM-ALK (Figure 2B).
Conjugation and Interactions between SUMO Modifiers and
Lys24 and Lys32 Residues of NPM-ALK
The SUMOplot algorithm analysis identified Lys24 and Lys32 of
NPM-ALK as having the highest probability to conjugate with the
SUMO modifiers (Supplemental Figure 1). To determine whether
the SUMO modifiers are indeed capable of conjugating with these
sites, wild-type NPM-ALK and NPM-ALK mutated at Lys24 or
Lys32 residues were translated in vitro using rabbit reticulocytes, and
levels of expression of the three constructs are depicted in Figure 3
Figure 2.NPM-ALK is conjugated and interacts with the SUMO proteins. (A) NPM-ALKwas immunoprecipitated in Karpas 299 and SR-786
cells, and the expression of the SUMO proteins was analyzed using WB. These studies showed that SUMO-1 and SUMO-2/3 are
physically associated with NPM-ALK protein as indicated by bands present in lane 2 where NPM-ALK was pulled down using an anti-ALK
antibody, but not in lanes 3 where normal mouse IgG was immunoprecipitated or in lane 4 where beads alone were used. In addition, a
control was used where NPM-ALK was pulled down using an anti-ALK antibody followed byWB using an anti-ALK antibody. Lane 1 (input)
demonstrates the corresponding NPM-ALK bands. (B) In the upper panel, NPM-ALK recombinant protein was generated by using the TnT
coupled rabbit reticulocyte kit. Thereafter, WB was performed to confirm the expression of the NPM-ALK recombinant protein. As
depicted in lane 1, there was no expression of NPM-ALK in rabbit reticulocyte lysate. In addition, WB demonstrated the presence of
recombinant NPM-ALK band in lane 2 and endogenous NPM-ALK band (80 kDa) in the lysate from Karpas 299 cells that were used as
control as shown in lane 3. In the lower panel, recombinant NPM-ALK protein was subjected to in vitro SUMOylation assay. Bands with a
molecular weight that is ~20 kDa higher than baseline NPM-ALK’s 80-kDa molecular weight were present in the lanes where incubations
with wild-type SUMO-1 (lane 1), SUMO-2 (lane 3), or SUMO-3 (lane 5) were performed. Importantly, incubation with the SUMO constructs
mutated at one amino acid (point mutation) showed much less pronounced higher-molecular weight bands in lanes 2 and 4. This band
was lacking in lane 6. did not show higher–molecular weight bands (lanes 2, 4, and 6).
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and showed that SUMOylation was abrogated for SUMO-1 and
SUMO-3 when NPM-ALKK24R mutant was used and for SUMO-3
only when NPM-ALKK32R was used (Figure 3, lower panel). In contrast,
mutations at Lys24 andLys32 failed to prevent SUMO-2 fromconjugation
with NPM-ALK, suggesting that SUMO-1 and SUMO-3 are most likely
the primary SUMO modifiers for NPM-ALK at these lysine residues.
SUMOylation Sustains the Stability of NPM-ALK Protein
To this end, we set to analyze the effects of SUMOylation on
NPM-ALK protein stability. Jurkat cells, which lack NPM-ALK but
express high levels of SUMO-1 andSUMO-2/3 proteins,were transfected
with wild-type NPM-ALK, NPM-ALKK24R, NPM-ALKK32R, or
NPM-ALKK24,32R plasmid and then treated with the protein
synthesis inhibitor CHX for 24 and 48 hours. WB analysis was
performed to measure the levels of expression of wild-type
NPM-ALK and its mutants (Figure 4). Of note is that wild-type
NPM-ALK did not demonstrate any significant degradation even
after 48 hours of treating the cells with CHX. At 24 hours, however,
NPM-ALKK32R and NPM-ALKK24,32R demonstrated minimal
degradation (data not shown). At 48 hours, the NPM-ALKK32R single
mutant demonstrated more degradation than the NPM-ALKK24R
single mutant. Notably, the degradation was much more pronouncedwhen the NPM-ALKK24,32R double mutant was used (Figure 4). These
data strongly suggest that SUMOylation maintains the stability of
NPM-ALK oncogenic protein.
De-SUMOylation by SENP1 Abrogates Nuclear and
Cytoplasmic Accumulation of NPM-ALK
To determine whether SUMOylation-mediated stabilization of
NPM-ALK occurs in the nucleus and/or the cytoplasm, Karpas 299
and SR-786 cells were transfected with EV or Myc-tagged SENP1
protease. Thereafter, subcellular fractionation and WB assay were
performed at 48 hours after transfection. There was more abundant
expression of NPM-ALK in the nucleus than the cytoplasm in cells
transfected with EV. This observation was more pronounced in the
SR-786 cells compared with Karpas 299 cells (Figure 5A). Moreover,
the expressions of SUMO-1 and SUMO-2/3 proteins were much
more pronounced in the nucleus than the cytoplasm. It is important
to note that fractionation and WB studies performed in Karpas 299
and SR-786 cells without transfection of EV demonstrated similar
patterns of expression of NPM-ALK and SUMO modifiers (data
not shown). These findings indicate that the subcellular distribu-
tion of NPM-ALK and SUMO modifiers was most likely not
related to the effects of the physical impact resulting from the
transfection procedure.
Figure 3. NPM-ALK is SUMOylated at Lys24 and Lys32 residues. The mutated NPM-ALK recombinant proteins NPM-ALKK24R and
NPM-ALKK32R were generated using the TnT coupled rabbit reticulocyte kit. In the upper panel, WB was performed to confirm the
expression of recombinant NPM-ALK proteins. Wild-type NPM-ALK recombinant protein is present in lane 1, NPM-ALKK24R recombinant
protein in lane 2, and NPM-ALKK32R recombinant protein in lane 3. In the lower panel, wild-type and mutated recombinant NPM-ALK
proteins were subjected to an in vitro SUMOylation assay. SUMOylation was abolished with the K24Rmutation for SUMO-1 and SUMO-3
and with the K32R mutation for SUMO-3. The two mutations failed to de-SUMOylate SUMO-2.
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decrease in the levels of SUMO-1 and SUMO-2/3 proteins. This
decrease was associated with substantial downregulation of
NPM-ALK protein expression (Figure 5A). To evaluate the efficiency
of SENP1 transfection, an immunofluorescence staining using an
anti-Myc antibody was performed at baseline (0 minute) and various
time points in Karpas 299 and SR-786 cells. Up to 1 hour, SENP1
was predominantly localized in the cytoplasm, but then at 3 to
6 hours, it became predominantly localized in the nucleus. At
24 hours, most of SENP1 shuttled back to the cytoplasm, whereas at
48 hours, very high levels of SENP1 were found to be distributed
between the nucleus and cytoplasm (Figure 5B).Figure 4. SUMOylation sustains the stability of NPM-ALK protein.
Jurkat cellswere transfectedwithwild-typeNPM-ALK, NPM-ALKK24R,
NPM-ALKK32R, or NPM-ALKK24,32R construct for 0, 24 or 48 hours
and then treated with the protein synthesis inhibitor CHX for an
additional 48 hours. There was minimal decrease in the levels of
NPM-ALK mutants at 24 hours (data not shown). Nonetheless, the
decrease in the expressions of NPM-ALKK32R wasmore pronounced
than the decrease in NPM-ALKK24R expression at 48 hours.
Importantly, this decrease was much more pronounced when the
NPM-ALKK24,32R double mutant was used. In contrast, wild-type
NPM-ALK protein expression did not show any evidence of
decreased expression even at 48 hours after treatment with CHX.
β-Actin shows equal loading of the proteins.De-SUMOylation by SENP1 Directs NPM-ALK Protein to
Ubiquitination
To investigate possible explanations for the decrease in NPM-ALK
levels after de-SUMOylation, pull down of the NPM-ALK protein
was performed followed by WB using an anti-SENP1, ALK, or
ubiquitin antibody. Transfection of EV shows high levels of
expression of basal NPM-ALK protein with small fractions associated
with SENP1 and ubiquitin (Figure 6). When SENP1 was
exogenously expressed, not only was the fraction of NPM-ALK
associated with SENP1 remarkably increased, but also the fraction
associated with ubiquitin was increased as well. Importantly, basal
levels of NPM-ALK decreased significantly after SENP1 transfection
(Figure 6). These results suggest that de-SUMOylation redirects the
NPM-ALK protein to the ubiquitination system, which leads to its
degradation and removal from the cell.
Cellular Effects of De-SUMOylation by SENP1 in NPM-ALK+
T-Cell Lymphoma
To study the cellular impact of antagonizing the SUMOylation
pathway in NPM-ALK+ T-cell lymphoma, forced expression of EV
or SENP1 was performed in Karpas 299, DEL, SR-786, and
SU-DHL-1 cells. The SENP1-mediated downregulation of SUMO-1
and SUMO-2/3 proteins as well as NPM-ALK (as shown in
Figure 5A) was associated with decreased NPM-ALK+ T-cell
lymphoma cell viability (Figure 7A), proliferation (Figure 7B), and
anchorage-independent colony formation (Figure 7C).
Discussion
In this paper, we provide novel evidence showing that there is an
upregulation of the SUMO modifiers SUMO-1, SUMO-2, and
SUMO-3 in NPM-ALK+ T-cell lymphoma cell lines and ALK+
T-cell lymphoma primary patient tumors compared with normal
human T lymphocytes. In contrast, the expression of the SENP1
protease, which physiologically induces de-SUMOylation through
removal of SUMO modifiers from their target proteins, was
substantially decreased in these lymphoma cell lines and primary
tumors. To our knowledge, only one screening study reported
Figure 5. SENP1-induced de-SUMOylation causes remarkable downregulation of NPM-ALK protein expression. (A) Karpas 299 and
SR-786 cells were transfected with EV or Myc-SENP1 expression plasmid. Myc tag was used to distinguish transfected SENP1 from the
very low levels of endogenously expressed SENP1 protein. Subcellular fractionation shows that in EV-transfected cells, SUMO-1 and
SUMO-2/3 proteins are exclusively localized in the nuclear (N) compartment with lack of expression in the cytoplasm (C). Although the
NPM-ALK protein is distributed between the nucleus and cytoplasm, it is slightly more abundant in the nucleus. It is important to mention
that similar patterns of expression of the SUMOmodifiers as well as NPM-ALK were seen in Karpas 299 and SR-786 cells under the basal
conditions without exposing the cells to the transfection stress (data not shown), supporting that these patterns of expression are
physiological. Notably, transfection of SENP1 induced remarkable downregulation of SUMO-1 and SUMO-2/3 proteins in the two cell
lines. The decrease in SUMO modifiers was associated with marked decrease in the nuclear and cytoplasmic expression of NPM-ALK.
Lamin A/C and β-actin were used as nuclear and cytoplasmic loading controls, respectively. (B) To examine whether adequate
transfection was achieved, immunofluorescence staining for Myc-SENP1 was performed, and its levels of expression were monitored for
up to 48 hours. Transfection of EV shows total lack of SENP1. Similarly, SENP1 was not detected either in Karpas 299 or in SR-786 cells
immediately after transfection at baseline. After 15 minutes, low levels of expression of SENP1 were identified in the cytoplasm. At 30/
60 minutes, the cytoplasmic expression of SENP1 became much more pronounced. Gradual shuttling of SENP1 into the nucleus
occurred, and it became distributed between the nucleus and cytoplasm at 3/6 hours. However, at 24 hours, most of SENP1 appeared to
be shuttling back to the cytoplasm, and yet at 48 hours, much higher levels of SENP1 were distributed between the nucleus and
cytoplasm.
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NPM-ALK+ T-cell lymphoma, but functional studies to charac-
terize the role of SUMO-1 were not performed in that study [51].
Herein, we found that NPM-ALK can be SUMOylated through
conjugation with the SUMO modifiers, which leads to sustaining
the stability of NPM-ALK protein. In support of this idea,
de-SUMOylation through exogenous expression of SENP1
downregulated the SUMO modifiers and was associated with
substantial decrease in NPM-ALK protein expression, which
reduced its accumulation in the nucleus and cytoplasm. Our
data suggest that the de-SUMOylating effects of SENP1 and the
subsequent decrease in NPM-ALK could be attributed, at least
partially, to promoting the association between NPM-ALK and
ubiquitin. At the cellular level, downregulation of the SUMO
modifiers resulted in negative biological effects, attesting to the
idea that the disruption of the SUMOylation pathway conveys
tumor-suppressing effects in NPM-ALK+ T-cell lymphoma.SUMOylation is a dynamic process that causes important
modifications of target proteins, which may alter their subcellular
localization and functional activity [16,17,31–34]. It has also been
proposed that an important outcome of SUMOylation is the
maintenance of protein stability by protecting targets from
proteasomal degradation [28–30]. Although SUMOylation is
important for physiological processes, it has also been shown to be
commonly deregulated in cancer cells [44–49]. In line with this idea,
our data showed that the SUMO proteins were overexpressed and
SENP1 protease was decreased in NPM-ALK+ T-cell lymphoma
relative to normal T lymphocytes. Indeed, SUMO-1, SUMO-2, and
SUMO-3 modifiers were all capable of conjugation with NPM-ALK.
The conjugation with the SUMO modifiers can occur through an
acceptor Lys residue within a ΨKX(D/E) SUMO consensus motif
present within the target protein, where Ψ is a large hydrophobic
amino acid residue [52]. In addition to the SUMO consensus motifs,
target proteins can sometimes conjugate noncovalently with the
Figure 6. SENP1-induced de-SUMOylation directs NPM-ALK to
ubiquitination. Transfection of EV demonstrates that most of
NPM-ALK protein is present in unbound form with much smaller
fractions conjugated to SENP1 or ubiquitin. To this end, exogenous
transfection of SENP1 expression plasmid induced remarkable
increase in NPM-ALK fraction that is associated with SENP1 or
ubiquitin, which was associated with substantial downregulation in
its unconjugated form. In lane 3, normal mouse IgG was used as a
negative control and immunoprecipitated instead of NPM-ALK.
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characterized by a short stretch of hydrophobic amino acids flanked
by acidic residues [53]. Herein, we were able to identify Lys24 and
Lys32 as acceptor residues located within potential SUMO consensusFigure 7. De-SUMOylation of NPM-ALK by SENP1 decreases cell viab
NPM-ALK+ T-cell lymphoma. (A) Transfection of Karpas 299, DEL,
plasmid resulted in a significant decrease in their viability after 4
transfection of the lymphoma cells with SENP1 decreased their pro
SENP1 also decreased the anchorage-independent colony formation
Representative examples of the colonies from each cell line are show
panels A, B, and C represent the means ± SE of three independentmotifs in NPM-ALK. A point mutation of Lys24 or Lys32 to arginine
abrogated the conjugation and interactions between NPM-ALK and
SUMO-1 and SUMO-3. In addition, this point mutation resulted
in degradation of NPM-ALK. The finding that the degradation of
the NPM-ALKK32R single mutant was more pronounced than
the degradation of the NPM-ALKK24R suggests that, individually, the
Lys32 residue may play a more significant role in sustaining the
stability of NPM-ALK protein. Notably, the degradation of the
NPM-ALK protein became much more pronounced when the two
lysine residues were simultaneously mutated to arginine. These
observations testify to the stabilizing effects of SUMO-1 and
SUMO-3, specifically through Lys24 and Lys32 residues, on
NPM-ALK protein. In contrast, mutations at the same residues
failed to abrogate the conjugation and interactions between
NPM-ALK and SUMO-2, suggesting that the interactions between
these two proteins could occur through other SUMO consensus
motifs that are present in NPM-ALK. The preferred conjugation and
interactions between NPM-ALK and SUMO-3 compared with
SUMO-2 may prove to be biologically relevant considering that
several recent studies demonstrated that SUMO-2 and SUMO-3
possess distinct biological functions in different types of cells [54–57].
Further studies are required to explore this point in NPM-ALK+
T-cell lymphoma.
SENPs have two primary functions including the conversion of
SUMO precursors to mature SUMO via removal of a portion of their
C-terminus and the reversal of the SUMOylation process via removalility, proliferation, and anchorage-independent colony formation of
SR-786, and SU-DHL-1 cells with the SENP1 protease expression
8 hours (*P b .001, **P b .0001, ***P b .00001). (B) In addition,
liferation (*P b .05, **P b .001, ***P b .00001). (C) Transfection of
potential of the different lymphoma cells (*P b .05, **P b .01). (D)
n at 7 days after transfection with EV or SENP1. Results shown in
experiments.
Figure 8. Proposed model for NPM-ALK SUMOylation. NPM-ALK forms heterodimers with wild-type NPM. These NPM/NPM-ALK
heterodimers possess ability to shuttle between the nucleus and cytoplasm. The association between NPM/NPM-ALK, through its Lys24
and Lys32 residues, with the SUMO proteins occurs predominantly in the nucleus, which is the cellular compartment where SUMO
proteins appear to be predominantly expressed in NPM-ALK+ T-cell lymphoma cells. In turn, conjugation with the SUMO modifiers
confers stability on NPM-ALK oncogenic protein by preventing its ubiquitination and degradation. Therefore, NPM/NPM-ALK is capable of
shuttling back to the cytoplasm. To this end, SUMOylation-mediated stability leads to accumulation and abundant expression of
NPM-ALK in the nucleus and cytoplasm. At the other hand, SENP1-mediated de-SUMOylation decreases significantly the expression and
accumulation of NPM/NPM-ALK in the nucleus and cytoplasm through the increase in NPM-ALK breakdown that occurs through the
switch from the protective effects of SUMOylation to the ubiquitination-induced degradation.
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processes contribute to the dynamic nature of SUMOylation. We
elected to evaluate SENP1 because of its ability to universally
de-SUMOylate the three SUMO modifiers, unlike other SENPs that
have preferential de-SUMOylation activities [58–61]. In our hands,
reestablishment of SENP1 in NPM-ALK+ T-cell lymphoma cells
resulted in decreasing the expression of the SUMO proteins, which
was associated with downregulation of NPM-ALK levels. Because
NPM-ALK plays central roles in driving the survival of this
lymphoma [1,2,62], its downregulation through de-SUMOylation
by SENP1 decreased lymphoma cell viability, proliferation, and
anchorage-independent colony formation.
The role of NPM in the pathogenesis of NPM-ALK+ T-cell
lymphoma remains intriguing. Previous studies showed that the
nuclear localization signal in NPM is not conserved in the NPM-ALK
chimeric protein. Therefore, nuclear translocation of NPM-ALK
occurs primarily because of the formation of heterodimers between
wild-type NPM and NPM-ALK [12]. Herein, we identified for the
first time SUMO consensus motifs that contain the Lys24 and Lys32
that are located within the NPM domain as the sites where SUMO
modifiers conjugate with NPM-ALK to maintain its stability. Similar
to NPM-ALK, previous studies showed that SENP1 is also capable of
shuttling between the nucleus and cytoplasm [58,63]. Indeed,
overexpression of SENP1 protein in NPM-ALK+ T-cell lymphoma
cells was associated with robust shuttling between the nucleus and
cytoplasm. The predominant localization of the SUMO modifiers in
the nucleus suggests that the interactions between the SUMO
modifiers, NPM-ALK, and SENP1 occur primarily in the nucleus.
The tendency of SUMOmodifiers to be colocalized with their targets
in the nucleus has been previously reported [31,33,52,64]. Our
results suggest a model in which the NPM/NPM-ALK heterodimers
translocate from the cytoplasm to the nucleus where they conjugateand interact with the SUMO modifiers. SUMOylation provides
stabilization of NPM/NPM-ALK, which leads to its nuclear
accumulation, followed by its shuttling back to the cytoplasm
(Figure 8). In line with our findings in NPM-ALK, previous studies
showed that SUMOylation plays an important role in the stability
and nuclear accumulation of several survival-regulatory proteins
[65–69]. However, it cannot be ruled out that, in addition to
SUMOylation, the localization of NPM/NPM-ALK heterodimers in
the nucleus may also be required for other yet unidentified biological
functions that are directly relevant to the survival of this lymphoma.
In addition to our novel data demonstrating direct contribution of
NPM to sustaining the stability of NPM-ALK protein through
SUMOylation, it is still possible that NPM contributes indirectly to
global SUMOylation of survival regulatory proteins in this lymphoma
in a fashion similar to what has been recently proposed in other
biological systems [70].
It has been shown that SUMOylation hinders protein-protein
interactions including the interactions with ubiquitin E1–activating
enzyme [71]. Furthermore, there have been studies indicating that
de-SUMOylation exposes ubiquitin-acceptor lysine residues located
within the target protein [72–74]. In the NPM-ALK+ T cell
lymphoma cells, de-SUMOylation of NPM-ALK led to an increase in
its association with ubiquitin, suggesting that SUMOylation has the
ability to prevent NPM-ALK from entering the proteasomal
degradation pathway. NPM-ALK has been previously demonstrated
to be ubiquitinated. Treating NPM-ALK+ T-cell lymphoma cells
with 7-AAG causes NPM-ALK to undergo proteasomal degradation
through Hsp70-dependent mechanism, although a specific Lys
residue for ubiquitination has not been identified [75]. In our
study, transfection with SENP1 resulted in de-SUMOylation, and
therefore it is possible that the Lys24 and Lys32 residues on
NPM-ALK became available for interaction with ubiquitin and
752 SUMOylation Sustains NPM-ALK Expression Vishwamitra et al. Neoplasia Vol. 17, No. 9, 2015subsequent proteasomal degradation. This idea was further illustrated
when the proteasome inhibitor MG132 abrogated the SENP1-
mediated downregulation of NPM-ALK (Supplemental Figure 2). To
this end, we currently do not have evidence that ubiquitin binds to
these specific residues, but entering NPM-ALK amino acid sequence
in ubiquitination prediction software (UbPred; www.ubpred.org)
demonstrated that it contains a potential ubiquitination site at Lys32.
Whether NPM-ALK binds ubiquitin at this residue or other residues
that may potentially interact with the SUMO proteins constitutes the
subject of future studies.
In summary, we have identified for the first time that aberrant
SUMOylation exists and contributes to the pathogenesis of
NPM-ALK+ T-cell lymphoma through maintaining the stability of
NPM-ALK oncogenic tyrosine kinase, which appears to promote its
nuclear localization and cellular accumulation. Forced expression of
SENP1 protease caused disruption of SUMOylation and subsequent
degradation of NPM-ALK, and thereby reduced the tumorigenic
potential of these lymphoma cells. Hence, SUMOylation may
represent a potential target for drug development to treat this
aggressive cancer.
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